Enantiomers of nifurtimox do not exhibit stereoselective anti-T. cruzi activity, toxicity or pharmacokinetic properties

by Moraes CB, White KL, Braillard S, Perez C, Goo J, Gaspar L, Shackleford DM, Cordeiro-da-Silva A, Thompson RC, Freitas-Junior L, Charman SA, Chatelain E. Antimicrobial Agents and Chemotherapy 2015, doi: 10.1128/AAC.05139-14.

Summary: With the aim of improving available drugs for the treatment of Chagas disease, individual enantiomers of nifurtimox were characterized. The results indicate that the enantiomers are equivalent in their in vitro activity against a panel of T. cruzi strains, in vivo efficacy in a murine model of Chagas disease, in vitro toxicity and ADME characteristics, and in vivo pharmacokinetic properties. There is unlikely to be any therapeutic benefit of an individual nifurtimox enantiomer over the racemic mixture.

Click here to read the article / PDF